Aro Biotherapeutics are a US company developing an alternative to ERT for Pompe disease; it’s a Substrate Reduction Therapy (SRT) that aims to reduce the glycogen stores in muscle cells that cause damage and loss of function. Its great to see that their technology has begun the journey towards regulatory approval.
Aro Biotherapeutics gets orphan drug designation to treat Pompe Disease (labiotech.eu)